Company Profile

Vitacyte LLC
Profile last edited on: 10/30/14      CAGE: 47HG0      UEI: CXWFTMJH33M6

Business Identifier: Tissue dissociating enzymes for specific cell isolation
Year Founded
2003
First Award
2004
Latest Award
2011
Program Status
Inactive
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

1102 Indiana Avenue
Indianapolis, IN 46202
   (317) 917-3457
   feedback@vitacyte.com
   www.vitacyte.com
Location: Single
Congr. District: 07
County: Marion

Public Profile

VitaCyte LLC manufactures highly purified and rigorously characterized tissue dissociating enzymes, which are sold as individual enzyme products or as enzyme formulations for specific cell isolation applications. These enzyme formulations are designed to achieve high viable cell yield, very low contaminant levels, and lot-to-lot consistency. The company's focus is on delivering a custom designed product in applications for isolating human or other mammalian cells from tissue to be used in research or clinical applications. VitaCyte offers purified collagenase and neutral protease products for tissue dissociation on a variety of tissue types. The firm’s CIzyme collagenase enzymes are offered at three different activity levels for applications on different tissue types. This approach reflects the knowledge from improved biochemical assays to understand C. histolyticum collagenase specific collagen degrading activities. Crude collagenases are purified and analyzed using a proprietary purification protocol and improved collagen-degrading assay (CDA) to quantitate each component. Collagenase at different activity levels have the ability to match traditional crude collagenases that work well with certain cell or tissue types using purified components in order to ensure greater reproducibility and benefit from the low endotoxin levels and insoluble components common in most crude collagenases. CIzyme collagenase and neutral protease enzymes are packaged separately to maintain the greatest long-term stability. Rigorous stability data assessments have shown the products to be stable as a lyophilized powder for 2 years when maintained as individual compone

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
5-9
Revenue Range
.5M-1M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2011 1 NIH $232,329
Project Title: Digital Image Analysis For Quantitative And Qualitative Assessment Of Pig Islets
2010 2 NIH $2,287,876
Project Title: Tissue Dissociation Enzymes for Islets & Other Cells
2007 1 NIH $276,028
Project Title: Improved recombinant collagenase for tissue dissociation
2006 1 NIH $195,331
Project Title: System to analyze factors affecting human islet yield

Key People / Management

  Robert C McCarthy -- President

  Andrew G Breite -- Senior Project Manager

  Francis Dwulet -- Chief Scientific Officer

  Michael Green -- Senior Scientist

  Charles Koehler -- Chief Financial Officer

  Dana F Rhorer -- Manufacturing Scientist

  Todd Walker -- Sales & Marketing Specialist

Company News

There are no news available.